This content is machine translated News in metastatic prostate cancer. What impact will the studies published in 2020/2021 have on clinical practice? The years 2020 and 2021 have brought some novelties in metastatic prostate cancer. Thus, with 177Lutetium-PSMA-617and the PARP inhibitor Olaparib, two new active substances are available. The latter is already… CME-Test
View Post 4 min This content is machine translated Biomarkers and immunotherapy New horizons in advanced prostate cancer Metastatic castration-resistant prostate cancer (mCRPC) has been considered primarily the domain of novel hormone and taxane therapy. Increasingly, however, other treatment approaches are being tested with sometimes promising results. In…
View Post 6 min This content is machine translated ESMO 2018 in Munich Quantum leap in ovarian cancer? The SOLO-1 trial was one of the “hot” topics at this year’s ESMO. A PFS improvement of 70% with good tolerance and efficacy not only in recurrences suggest a relevant…
